Triple
T5981335
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | EMERGE (Study 302) |
E133123
|
entity |
| Predicate | coDeveloperCompany |
P6901
|
FINISHED |
| Object | Eisai |
E24939
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Eisai | Statement: [EMERGE (Study 302), coDeveloperCompany, Eisai]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Eisai Context triple: [EMERGE (Study 302), coDeveloperCompany, Eisai]
-
A.
Eisai
chosen
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
B.
Eisai
Eisai was a Japanese Buddhist monk of the Kamakura period best known for introducing Rinzai Zen and promoting tea culture in Japan.
-
C.
Chugai Pharmaceutical
Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
-
D.
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company is a leading global biopharmaceutical firm headquartered in Japan, focused on developing innovative medicines in areas such as oncology, gastroenterology, neuroscience, and rare diseases.
-
E.
Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company known for developing prescription drugs and biopharmaceuticals, including treatments for neurological and autoimmune diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: coDeveloperCompany Context triple: [EMERGE (Study 302), coDeveloperCompany, Eisai]
-
A.
coDeveloperOf
chosen
Indicates that two or more entities jointly developed or collaborated in creating the same project, product, or work.
-
B.
majorDeveloper
Indicates that an entity is a primary or leading developer responsible for creating or significantly contributing to another entity.
-
C.
coFounderCompany
Indicates that a person is one of the founding members who jointly established a particular company.
-
D.
hasDevelopmentStudioIn
Indicates that an entity has a development studio located in a specified place.
-
E.
isDevelopedBy
Indicates that something (such as a product, project, or idea) is created, produced, or brought into existence through the work or effort of a particular developer or group of developers.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0086f45e8819098f73dd16d45ec9d |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04a6921b081908a6f6323d5c7a062 |
completed | March 22, 2026, 8 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c10847cdec81908a4d2d19d8a53d1d |
completed | March 23, 2026, 9:30 a.m. |
| PD | Predicate disambiguation | batch_69c049de98648190962b14fd341c93da |
completed | March 22, 2026, 7:58 p.m. |
Created at: March 22, 2026, 4:04 p.m.